Clinical data
Trade names Aldomet, Aldoril, Dopamet, others
AHFS/ Monograph
MedlinePlus a682242
  • AU: A
  • US: B (No risk in non-human studies)
Routes of
Oral, IV
ATC code C02AB01 (WHO)
C02AB02 (WHO) (racemic)
Legal status
Legal status
Pharmacokinetic data
Bioavailability approximately 50%
Metabolism Hepatic
Biological half-life 105 minutes
Excretion Renal for metabolites
Synonyms L-α-Methyl-3,4-dihydroxyphenylalanine
CAS Number 555-30-6 YesY
PubChem (CID) 38853
CID 40175
DrugBank DB00968 YesY
ChemSpider 35562 N
UNII 56LH93261Y YesY
ECHA InfoCard 100.008.264
Chemical and physical data
Formula C10H13NO4
Molar mass 211.215 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)
Wikimedia Commons has media related to Methyldopa.

Methyldopa, sold under the brand name Aldomet among others, is a centrally acting antihypertensive agent. Its is no longer frequently used following the introduction of alternative safer classes of agents. However, it continues to have a role in otherwise difficult to treat hypertension and gestational hypertension.

It is metabolized to alpha-methylnorepinephrine in the brain, and this compound is thought to activate central alpha-2 adrenergic receptors (Gerber, 1990). Being a selective agonist for α2 adrenergic receptors, psychoactive drug is used as a sympatholytic or antihypertensive.

Methydopa was discovered in 1960.[1] It is on the World Health Organization's List of Essential Medicines, the most important medication needed in a basic health system.[2]

Medical uses

Methyldopa is used in the clinical treatment of the following disorders:

Side effects

Methyldopa is capable of inducing a number of adverse side effects, which range from mild to severe. Nevertheless, they are generally mild when the dose is less than 1 gram per day.[3] Side effects may include:


Rebound hypertension via withdrawal on account of tolerance upon the abrupt discontinuation of methyldopa has been reported.[4]

Mechanism of Action

Methyldopa has a dual mechanism of action:


Methyldopa exhibits variable absorption from the gastrointestinal tract. It is metabolized in the liver and intestines and is excreted in urine.


When methyldopa was first introduced, it was the mainstay of antihypertensive treatment, but its use has declined on account of relatively severe adverse side effects, with increased use of other safer and more tolerable agents such as alpha blockers, beta blockers, and calcium channel blockers. Additionally, it has yet to be associated with reducing adverse cardiovascular events including myocardial infarction and stroke, or overall all-cause mortality reduction in clinical trials.[5] Nonetheless, one of methyldopa's still current indications is in the management of pregnancy-induced hypertension (PIH), as it is relatively safe in pregnancy compared to many other antihypertensives which may affect the fetus.

See also


  1. Walker, S. R. (2012). Trends and Changes in Drug Research and Development. Springer Science & Business Media. p. 109. ISBN 9789400926592.
  2. "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.
  3. British National Formulary 56. September 2008. pp. 95–96. ISBN 978-0-85369-778-7.
  4. Methyldopa (PIM 342)
  5. Mah GT, Tejani AM, Musini VM. Methyldopa for primary hypertension. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD003893. DOI: 10.1002/14651858.CD003893.pub3.
This article is issued from Wikipedia - version of the 9/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.